Ipca Laboratories Limited announced its unaudited financial results for the first quarter ended 30th June, 2009 of the financial year 2009-10.
Key Highlights of Q1 FY10
— Net Total Income at Rs. 363.05 crores in Q1 FY10 as against Rs. 295.30 crores in Q1 FY09, growth of 23%.
— Export Income at Rs. 175.20 crores in Q1 FY10 as against Rs. 152.52 crores in Q1 FY09, growth of 15%.
— Revenue from Indian branded formulations business at Rs. 144.90 crores in Q1 FY10 as against Rs. 116.39 crores in Q1 FY09, growth of 24%.
— Export Revenue from formulations at Rs. 94.63 crores in Q1 FY10 as against Rs. 89.00 crores in Q1 FY09, growth of 6%.
— Revenue from formulations business at Rs. 239.53 crores in Q1 FY10 as against Rs. 205.39 crores in Q1 FY09, growth of 17%.
— Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs.37.67 crores in Q1 FY10 as against Rs. 23.85 crores in Q1 FY09, growth of 58%.
— Export Revenue from Active Pharmaceutical Ingredients (APIs) at Rs.80.57crores in Q1 FY10 as against Rs. 63.52 crores in Q1 FY09, growth of 27%.
— Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 118.24 crores in Q1 FY10 as against Rs. 87.37 crores in Q1 FY09, growth of 35%.
— EBITDA at Rs. 71.86 crores in Q1 FY10 as against Rs. 59.54 crores in Q1 FY09, growth of 21%.
— EBITDA margin @ 20%.
— Net Profit at Rs. 49.77 crores in Q1 FY10 as against Rs. 23.63 crores in Q1 FY09, growth of 111%.
— EPS of Rs. 19.86 in Q1 FY10 as against Rs. 9.38 in Q1 FY09.
— Till date, the Company has filed 13 ANDAs with US-FDA out of which 9 ANDAs are granted.
— 46 DMFs are also filed with US-FDA for Active Pharmaceutical Ingredients (APIs).
